Images List Premium Download Classic

Pharmaceutically Acceptable Salt

Pharmaceutically Acceptable Salt-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Inhibitors of histone deacetylase
April 12, 2018 - N°20180099977

Or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein u, j, v, x, r2a, r2b, r2c, r5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. ...
Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
April 12, 2018 - N°20180099967

And pharmaceutically acceptable salts thereof, wherein r1, r2 and r3 are as defined herein. The present invention also relates to compositions comprising at least one fused tricyclic heterocyclic compound, and methods of using the fused tricyclic heterocyclic compounds for treating or preventing hiv infection in a subject.
Tricyclic compound and jak inhibitor
April 12, 2018 - N°20180099966

Novel tricyclic compound represented by the formula (i), the formula (ii) or the formula (iii) (wherein: each of a1, a2 and a3 is a cyclohexane-1,4-diyl group or the like; each of l1, l2 and l3 is a methylene group or the like; each of x1 and x3 is 0 or nh; each of r1 and r3 is a cyano c1...
Pharmaceutically Acceptable Salt Patent Pack
Download 1713+ patent application PDFs
Pharmaceutically Acceptable Salt Patent Applications
Download 1713+ Pharmaceutically Acceptable Salt-related PDFs
For professional research & prior art discovery
inventor
  • 1713+ full patent PDF documents of Pharmaceutically Acceptable Salt-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Naphthyridine compounds, medical combinations and use thereof
Wuhan Novaffey Science & Technology Co., Ltd.
April 12, 2018 - N°20180099962

This invention involves the field of biomedicine, and reveals naphthyridine compounds, medical combinations and use thereof. The naphthyridine compounds has the structure as shown by formula (i), or its stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or their prodrugs. The naphthyridine compounds of this invention has anti-tumor efficacy significantly superior to that of prior art. ...
Pyrrolidine gpr40 modulators
April 12, 2018 - N°20180099949

Or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are gpr40 g protein-coupled receptor modulators which may be used as medicaments.
Quinazoline derivatives as vegf inhibitors
Genzyme Corporation
April 12, 2018 - N°20180099946

The invention relates to quinazoline derivatives of formula (i), wherein m is an integer from 1 to 3; r1 represents halogeno or c1-3alkyl; x1 represents —o—; r2 is selected from one of the following three groups: 1) c1-5alkylr3 (wherein r3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, c1-4 alkyl, ...
Pharmaceutically Acceptable Salt Patent Pack
Download 1713+ patent application PDFs
Pharmaceutically Acceptable Salt Patent Applications
Download 1713+ Pharmaceutically Acceptable Salt-related PDFs
For professional research & prior art discovery
inventor
  • 1713+ full patent PDF documents of Pharmaceutically Acceptable Salt-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Chitosan covalently linked with small molecule integrin antagonist for targeted delivery
Hoffmann-la Roche Inc.
April 12, 2018 - N°20180099005

The invention relates to the chitosan polymer derivatives of formula i: and pharmaceutically acceptable salts and esters thereof, wherein y, x1, x4, r1, r2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula i bind to or associate with alpha-4-beta-1 (α4β1) and alpha-v-beta-3 (α vβ3) integrin ...
Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis
Millennium Pharmaceuticals, Inc.
April 12, 2018 - N°20180099000

The present invention provides a method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis in a patient in need thereof, which comprises administering an effective amount of [(1r)-1-({[2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid or a citric acid ester thereof, or a pharmaceutically acceptable salt thereof to the patient.
Pharmaceutical doses for a bromodomain and extraterminal protein (bet) inhibitor
Oncoethix Gmbh
April 12, 2018 - N°20180098997

The invention is a method for treating patients with cancer comprising administering to the patient a safe and effective dose of (s)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-n-(4-hydroxyphenyl)acetamideor a pharmaceutically acceptable salt or hydrate thereof, wherein the dose is between about 40 mg once per per day and about 120 mg once per ...
Combination products with tyrosine kinase inhibitors and their use
Novartis Ag
April 12, 2018 - N°20180098995

The present invention relates to pharmaceutical products comprising a combination of (i) a met inhibitor and (ii) an egfr inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related invention embodiments.
Histone deacetylase inhibitor, and preparation method and use thereof
Guangdong Zhongsheng Pharmaceutical Co., Ltd
April 12, 2018 - N°20180098990

A compound represented by formula i or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims ...
Prmt5 inhibitors and uses thereof
Epizyme, Inc.
April 12, 2018 - N°20180098987

Described herein are compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity. Methods of using the compounds for treating prmt5-mediated disorders are also described.
Oral pharmaceutical composition of methylergonovine and methods of use thereof
Lupin Atlantis Holdings Sa
April 12, 2018 - N°20180098982

A solid pharmaceutical oral composition for once daily administration is provided. The composition includes from about 0. 5 mg to about 0. 8 mg in total of methylergonovine or a pharmaceutically acceptable salt thereof. The composition is used for treating a subject having a methylergonovine responsive condition such as migraine, refractory migraine, uterine atony, uterine haemorrhage, subinvolution of the uterus, and uterine haemorrhage in ...
Pharmaceutically Acceptable Salt Patent Pack
Download 1713+ patent application PDFs
Pharmaceutically Acceptable Salt Patent Applications
Download 1713+ Pharmaceutically Acceptable Salt-related PDFs
For professional research & prior art discovery
inventor
  • 1713+ full patent PDF documents of Pharmaceutically Acceptable Salt-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pramipexole transdermal delivery system and uses thereof
Transwell Biotech Co., Ltd.
April 12, 2018 - N°20180098973

A pramipexole transdermal patch for treatment of neurological disorders including parkinson's disease that may be administered on a daily basis. The pramipexole transdermal patch of the present invention preferably comprises a drug-containing layer that comprises pramipexole or a pharmaceutically acceptable salt thereof at 2% to about 15% by weight of the dru-containing layer and at least two acrylic polymers wherein each polymer ...
Hodgkin lymphoma therapy
April 12, 2018 - N°20180098969

A combination of said compound of formula i or a pharmaceutically acceptable salt thereof with brentuximab vedotin and a method of treating hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said combination.
Lasofoxifene treatment of breast cancer
Duke University
April 12, 2018 - N°20180098963

The disclosure provides methods for treating estrogen receptor positive (er+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the estrogen receptor 1 (esr1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant er+ cancers.
Composition for preventing and treating pancreatitis containing naphthoquinone-based compound as active ingredient
Nadianbio
April 12, 2018 - N°20180098960

The present invention relates to a composition for the prevention and treatment of pancreatitis comprising a naphthoquinone-based compound, a pharmaceutically acceptable salt, a prodrug, a solvate, or an isomer of the same. Particularly, the naphthoquinone-based compounds β-lapachone and dunnione can reduce the pancreatic weight/body weight ratio, which is increased by pancreatitis; reduce the increased activities of digestive ...
Oral pharmaceutical composition of methylergonovine and methods of use thereof
Lupin Atlantis Holdings Sa
April 12, 2018 - N°20180098942

A solid pharmaceutical oral composition for twice daily administration is provided. The composition includes from about 0. 3 mg to about 0. 6 mg in total of methylergonovine or a pharmaceutically acceptable salt thereof. The composition is used for treating a subject having a methylergonovine responsive condition such as migraine, refractory migraine, uterine atony, uterine haemorrhage, subinvolution of the uterus, and uterine haemorrhage in ...
Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
April 05, 2018 - N°20180093999

Wherein r1 to r5 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
Indole derivatives
Richter Gedeon Nyrt.
April 05, 2018 - N°20180093989

The present invention relates to compounds of the general form (i). The present invention relates to new substituted diazepino-indole derivatives of the general formula (i), and to pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising such compounds, to new intermediate thereof as well as to the use of such compounds in treatment or prevention of disorders associated ...
2-acylaminopropoanol-type glucosylceramide synthase inhibitors
April 05, 2018 - N°20180093981

Or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by structural formula (i) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by structural formula (i) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; ...
Loading